Fideuram Asset Management Ireland dac Purchases New Shares in Medtronic PLC $MDT

Fideuram Asset Management Ireland dac purchased a new stake in shares of Medtronic PLC (NYSE:MDT) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 17,953 shares of the medical technology company’s stock, valued at approximately $1,652,000.

A number of other large investors also recently made changes to their positions in MDT. Brighton Jones LLC lifted its position in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the last quarter. Jump Financial LLC purchased a new stake in Medtronic during the second quarter worth about $299,000. Main Street Financial Solutions LLC increased its holdings in Medtronic by 28.9% during the second quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after buying an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC increased its holdings in Medtronic by 21.3% during the second quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after buying an additional 3,376 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Medtronic Trading Down 2.4%

MDT stock opened at $73.73 on Friday. The company has a market capitalization of $94.66 billion, a PE ratio of 20.54, a price-to-earnings-growth ratio of 1.80 and a beta of 0.62. Medtronic PLC has a one year low of $73.67 and a one year high of $106.33. The company’s 50 day moving average price is $82.36 and its two-hundred day moving average price is $92.65. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.9%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Analysts Set New Price Targets

A number of research firms recently issued reports on MDT. Evercore set a $106.00 price objective on shares of Medtronic and gave the stock an “outperform” rating in a report on Thursday, April 9th. Robert W. Baird raised their price objective on shares of Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Daiwa Securities Group cut their target price on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Piper Sandler cut their target price on shares of Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research report on Wednesday, April 1st. Finally, CICC Research assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “outperform” rating for the company. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.45.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).